• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 144 filed by Alector Inc.

    5/30/25 5:10:20 PM ET
    $ALEC
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $ALEC alert in real time by email
    Form 144 Filer Information UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    Form 144

    NOTICE OF PROPOSED SALE OF SECURITIES
    PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933

    FORM 144

    144: Filer Information

    Filer CIK
    0001895592
    Filer CCC
    XXXXXXXX
    Is this a LIVE or TEST Filing? Radio button checked LIVE Radio button not checked TEST

    Submission Contact Information

    Name
    Phone
    E-Mail Address

    144: Issuer Information

    Name of Issuer
    Alector, Inc.
    SEC File Number
    001-38792
    Address of Issuer
    131 Oyster Point Blvd.
    Suite 600
    South San Francisco
    CALIFORNIA
    94080
    Phone
    (415)-231-5660
    Name of Person for Whose Account the Securities are To Be Sold
    Sara Kenkare-Mitra
    See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

    Relationship to Issuer
    Officer

    144: Securities Information

    Title of the Class of Securities To Be SoldName and Address of the BrokerNumber of Shares or Other Units To Be SoldAggregate Market ValueNumber of Shares or Other Units OutstandingApproximate Date of SaleName the Securities Exchange
    Common Stock
    Morgan Stanley Smith Barney LLC Executive Services
    200 W Civic Center Dr.
    4th Floor
    Sandy � UT � 84070
    2302030616.69999260006/02/2025
    Nasdaq


    Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

    144: Securities To Be Sold

    Title of the ClassDate you AcquiredNature of Acquisition TransactionName of Person from Whom AcquiredIs this a Gift?Date Donor AcquiredAmount of Securities AcquiredDate of PaymentNature of Payment *
    Common Stock05/30/2025Vesting of Restricted Stock UnitsIssuerCheckbox not checked4533105/30/2025(1)

    * If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.



    Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

    144: Securities Sold During The Past 3 Months

    Name and Address of SellerTitle of Securities SoldDate of SaleAmount of Securities SoldGross Proceeds
    Sara Kenkare-Mitra
    C/O Alector, Inc.
    131 Oyster Point Blvd., Suite 600
    South San Francisco � CA � 94080
    Common Stock03/03/20252907342660.44

    144: Remarks and Signature

    Remarks
    (1) The securities to be sold were received upon the settlement of vested restricted stock units, or RSUs. The reported shares will be sold to satisfy the reporting person's tax obligations in connection with the vesting of RSUs.
    Date of Notice
    05/30/2025

    ATTENTION:

    The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
    Signature
    /s/ Cameron Hagen, by power of attorney

    ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

    Get the next $ALEC alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $ALEC

    DatePrice TargetRatingAnalyst
    12/17/2024$9.00 → $2.50Outperform → Neutral
    Mizuho
    12/16/2024$4.00Buy → Hold
    Stifel
    12/4/2024$9.00 → $1.00Neutral → Underperform
    BofA Securities
    11/29/2024$35.00 → $7.00Buy
    H.C. Wainwright
    11/26/2024$10.00 → $3.00Equal-Weight → Underweight
    Morgan Stanley
    12/14/2023$8.00 → $15.00Hold → Buy
    Stifel
    12/12/2023$12.00Buy
    Deutsche Bank
    9/25/2023$4.00Sell
    Goldman
    More analyst ratings

    $ALEC
    SEC Filings

    See more
    • SEC Form 8-K filed by Alector Inc.

      8-K - Alector, Inc. (0001653087) (Filer)

      6/13/25 4:06:01 PM ET
      $ALEC
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 144 filed by Alector Inc.

      144 - Alector, Inc. (0001653087) (Subject)

      5/30/25 5:10:20 PM ET
      $ALEC
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 10-Q filed by Alector Inc.

      10-Q - Alector, Inc. (0001653087) (Filer)

      5/8/25 4:15:17 PM ET
      $ALEC
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $ALEC
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Alector Provides Executive Leadership Update

      -- Neil Berkley, M.B.A., appointed Interim Chief Financial Officer, succeeding Marc Grasso, M.D., effective June 20, 2025 -- SOUTH SAN FRANCISCO, Calif., June 13, 2025 (GLOBE NEWSWIRE) -- Alector, Inc. (NASDAQ:ALEC), a late-stage clinical biotechnology company focused on developing therapies to counteract the devastating progression of neurodegeneration, today announced that its Chief Financial Officer (CFO), Marc Grasso, M.D., will conclude his tenure with the company, effective June 20, 2025, to pursue other opportunities. Neil Berkley, M.B.A., the company's Chief Business Officer, will assume the role of Interim CFO while continuing in his current position. "Marc has been a valuab

      6/13/25 4:05:00 PM ET
      $ALEC
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Alector to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference

      SOUTH SAN FRANCISCO, Calif., June 03, 2025 (GLOBE NEWSWIRE) -- Alector, Inc. (NASDAQ:ALEC), a late-stage clinical biotechnology company focused on developing therapies to counteract the devastating progression of neurodegeneration, today announced that management will participate in a fireside chat at the Goldman Sachs 46th Annual Global Healthcare Conference on Tuesday, June 10, 2024, at 8:40 am ET. A live webcast of the fireside chat will be available on the "Events & Presentations" page within the Investors section of the Alector website at http://investors.alector.com. A replay will be available on the Alector website for 90 days following the event. About AlectorAlector is a late-st

      6/3/25 8:00:00 AM ET
      $ALEC
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Alector Reports First Quarter 2025 Financial Results and Provides Business Update

      Topline data from pivotal INFRONT-3 Phase 3 clinical trial of latozinemab in FTD-GRN on track for Q4 2025 Completed enrollment in PROGRESS-AD Phase 2 clinical trial of AL101 in early Alzheimer's disease Continuing to pursue Alector Brain Carrier programs, including the company's anti-amyloid beta antibody and its GCase enzyme replacement therapy Extending runway into the second half of 2027, with $354.6 million in cash, cash equivalents, and investments SOUTH SAN FRANCISCO, Calif., May 08, 2025 (GLOBE NEWSWIRE) -- Alector, Inc. (NASDAQ:ALEC), a late-stage clinical biotechnology company focused on developing therapies to counteract the devastating progression of neurodegeneration, toda

      5/8/25 4:05:00 PM ET
      $ALEC
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care